Document:

EXHIBIT 4.18

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (this “Agreement”) is made as of ____________, 2014 by and among BONE BIOLOGICS, CORP., a Delaware
corporation (the “Company”), MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC., a California Corporation (“MTF”),
AFH HOLDING AND ADVISORY, LLC, a Delaware limited liability company (“AFH”) and HANKY INVESTMENT COMPANY, L.P.
(‘HIC’) (MTF, HIC and AFH each a “Stockholder” and collectively referred to as the “Stockholders”).

 

RECITALS

 

A.The Company, AFH
Acquisition X, Inc. (“AFH Acquisition”), a wholly-owned subsidiary of AFH, Bone Biologics Acquisition Corp.,
a wholly-owned subsidiary of AFH Acquisition (“Merger Sub”), and Bone Biologics, Inc. (“Bone Bio”)
has entered into that certain Agreement and Plan of Merger, dated ______________ (the “Merger Agreement”)

 

B. Under the terms of the
Merger Agreement, the Merger Sub merged with and into Bone Bio, the separate corporate existence of Merger Sub ceased and the Bone
Bio continued as the surviving corporation and a wholly owned subsidiary of AFH Acquisition (the “Merger”).
In connection with the Merger, AFH Acquisition changed its name to Bone Biologics, Corp., herein also referred to as the “Company.”

 

C. The Stockholders
hold certain shares of common stock, par value $ 0.001 (“Common Stock”), in the Company (the “Shares”).

 

D. Pursuant to the terms
of the Merger Agreement, MTF and AFH have certain demand registration rights and unlimited piggyback registration rights for the
Shares.

 

AGREEMENTS

 

In consideration of the
premises and the mutual covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.Definitions. In addition to
terms defined elsewhere herein, as used in this Agreement, the terms:

 

“Affiliate”
of any particular person or entity means any other person or entity controlling, controlled by or under common control with such
particular person or entity and, for any person that is a partnership, will also include any general or limited partner of such
partnership.

 

“Business Day”
means any day other than Saturday, Sunday, or a day on which commercial banks in California or New York are obligated by any legal
requirement to close.

 

    	 

    	 

    

 

“Commission”
means the Securities and Exchange Commission.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Initial Public Offering”
means the Company’s first underwritten Public Offering.

 

“Public Offering”
means any offering by the Company of its equity securities to the public pursuant to an effective registration statement under
the Securities Act or any comparable statement under any comparable federal statute then in effect.

 

“Registrable Shares”
means at any time (i) any shares of Common Stock beneficially held, directly or indirectly, by MTF, HIC and AFH as of the date
of this agreement, respectively; and (ii) any shares of Common Stock then issuable directly or indirectly upon the conversion or
exercise of other securities or which were issued as a dividend or other distribution with respect to or in replacement of such
shares referred to in (i); provided, however, that Registrable Shares shall not include any shares which have been sold pursuant
to an effective registration statement under the Securities Act or which have been sold to the public pursuant to Rule 144 under
the Securities Act or any other available exemption to the Securities Act. For purposes of this Agreement, a person will be deemed
to be a holder of Registrable Shares whenever such person has the then existing right to acquire such Registrable Shares (by conversion
or otherwise), whether or not such acquisition actually has been effected (it being understood, however, that any Registrable Shares
which are not shares of Common Stock shall be converted into or exercised for shares of Common Stock immediately prior to the filing
of any registration pursuant to which such Common Stock is to be registered).

 

“Securities Act”
means the Securities Act of 1933, as amended.

 

2.Demand Registration.

 

2.1Requests
for Registration. Subject to the terms of this Agreement, on or before thirty (30) days after the date the Current Form 8K
regarding the Merger Agreement is filed with the Commission (the “8K Filing Date”), the Company will seek registration
under the Securities Act of all or part of their Registrable Shares on Form S-1 or any similar long-form registration (“Long-Form
Registration”) or, if available, on Form S-2 or S-3 or any similar short-form registration (“Short-Form Registration”)
(either of such registrations, a “Demand Registration”). Within five (5) days of the 8K Filing Date, the Company
will, subject to Section 2.2 below, give written notice of its intent to make a Demand Registration to all other holders of Registrable
Shares and will include in such registration all Registrable Shares with respect to which the Company has received written requests
for inclusion within twenty-five (25) days after delivery of the Company’s notice. MTF, HIC and AFH will each be entitled
to request two (2) Long-Form Registrations or Short-Form Registrations, in which the Company will pay, in each case, all Registration
Expenses (as defined in Section 6 below). A registration will not constitute one of the permitted Demand Registrations until it
has become effective and the holder of the Registrable Shares, as applicable, have been able to register and sell at least fifty
percent (50%) of its Registrable Shares, respectively, requested to be included in such registration. The Company shall be entitled
to include in any Demand Registration shares to be sold by the Company for its own account, provided that in the event that the
number of shares included by the Company exceeds fifty percent (50%) of the shares registered in such registration, such registration
will not count as a Demand Registration hereunder.

 

    	2

    	 

    

 

2.2Priority.
The Company will include in any Demand Registration any Registrable Shares, or any other securities; provided, however, if the
Demand Registration is an underwritten offering and the managing underwriter(s) advise the Company in writing that in their opinion
the number of securities requested to be included exceeds the number of securities which can reasonably be sold in such offering,
the Company will include in such registration, first, the Registrable Shares requested to be included in such Demand Registration
pro rata among the holders of such Registrable Shares on the basis of the number of shares which such holders requested
to be included in such registration, and second, the other securities to be included in such Demand Registration pro
rata among the holders of such shares on the basis of the number of shares which such holders requested to be included in
such registration.

 

2.3Selection of
Underwriters. MTF and AFH, as applicable, shall have the right to select the managing underwriter(s) to administer the offering
anticipated by any of their Demand Registrations, subject, in each case, to the Company’s approval which will not be unreasonably
withheld or delayed, and the Company shall have the right to select the managing underwriters for all other registrations and provided
further that such managing underwriter(s) selected by MTF and AFH as applicable, shall be qualified nationally recognized underwriters.
In the event that MTF and/or AFH shall have selected an underwriter, such Stockholder shall be required to pay any expenses related
to such underwriter including any legal expenses of the Company related to such offering.

 

3.Piggyback Registration.

 

3.1Right to
Piggyback. Whenever the Company proposes to register any of its securities under the Securities Act (other than pursuant to
a Demand Registration hereunder) and the registration form to be used may be used for the registration of any Registrable Shares
(a “Piggyback Registration”), the Company will give prompt written notice to all holders of the Registrable
Shares of its intention to effect such a registration and will include in such registration all Registrable Shares (in accordance
with the priorities set forth in Sections 3.2 and 3.3 below) with respect to which the Company has received written requests
for inclusion within fifteen (15) days after the delivery of the Company’s notice.

 

3.2Priority
on Primary Registrations. If a Piggyback Registration is an underwritten primary registration on behalf of the Company and
the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included
in such registration exceeds the number which can reasonably be sold in such offering, the Company will include in such registration
first, the securities that the Company proposes to sell, second, the Registrable Shares requested to be included
in such registration, pro rata among the holders of such Registrable Shares on the basis of the number of shares
which such holders requested to be included in such registration, and third, other securities requested to be included in
such registration.

 

    	3

    	 

    

 

3.3Priority
on Secondary Registrations. If a Piggyback Registration is an underwritten secondary registration on behalf of holders of the
Company’s securities other than a Demand Registration and the managing underwriters advise the Company in writing that in
their opinion the number of securities requested to be included in such registration exceeds the number which can reasonably be
sold in such offering, the Company will include in such registration first, the securities requested to be included therein
by the holders requesting such registration, the Registrable Shares requested to be included in such registration, pro rata
among the holders of such securities on the basis of the number of shares which by such holders requested to be included in such
registration, and, second, other securities requested to be included in such registration.

3.4Selection
of Underwriters. In connection with any Piggyback Registration in which MTF and/or AFH elected to include Registrable Shares,
the Company shall have the right to select the managing underwriters.

 

4.Holdback Agreements.

 

4.1Holders’
Agreements. Each holder of Registrable Shares agrees not to effect any public sale or distribution of equity securities of
the Company, or any securities convertible into or exchangeable or exercisable for such securities, during the six (6) months following,
the effective date of the Merger Agreement.

 

5.Registration
Procedures. Whenever the holders of Registrable Shares have requested that any Registrable Shares be registered pursuant to
this Agreement, the Company will use its commercially reasonable best efforts to effect the registration of such Registrable Shares
in accordance with the terms of this Agreement.

 

(a)prepare
and file with the Commission a registration statement with respect to such Registrable Shares and use its best efforts to cause
such registration statement to become effective (provided that before filing a registration statement or prospectus, or any amendments
or supplements thereto, the Company will furnish copies of all such documents proposed to be filed to the counsel or counsels for
the sellers of the Registrable Shares covered by such registration statement);

(b)prepare
and file with the Commission such amendments and supplements to such registration statement and the prospectus(es) used in connection
therewith as may be necessary to keep such registration statement effective for a period of not less than twelve months or until
all Registrable Securities registered pursuant to such registration statement have been sold.

(c)notify
each seller of such Registrable Shares, at any time when a prospectus relating thereto is required to be delivered under the Securities
Act, of the happening of any event as a result of which the prospectus included in such registration statement contains an untrue
statement of a material fact or omits any fact necessary to make the statements therein not misleading and, at the request of any
such seller, the Company will use commercially reasonable efforts to prepare a supplement or amendment to such prospectus so that,
as thereafter delivered to the sellers of such Registrable Shares, such prospectus will not contain any untrue statement of a material
fact or omit to state any fact necessary to make the statements therein not misleading.

 

    	4

    	 

    

(d)use
commercially reasonable efforts to cause all such Registrable Shares to be listed on each securities exchange or national quotation
system on which similar securities issued by the Company are then listed or quoted;

 

(e)enter
into an underwriting agreement in customary form if requested by the holders of a majority of the Registrable Shares being sold
or the underwriters, if any, reasonably request in order to facilitate the disposition of such Registrable Shares;

(f)advise each stockholder
of such Registrable Shares, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order
by the Commission suspending the effectiveness of such registration statement or preventing the use of any related prospectus or
suspending the qualification of any Common Stock included in such registration statement for sale in any jurisdiction or the initiation
or threatening of any proceeding for such purpose and promptly use all reasonable efforts to prevent the issuance of any stop order
or to obtain its withdrawal if such stop order should be issued;

 

(g)at
least forty eight (48) hours prior to the filing of any registration statement or prospectus, or any amendment or supplement to
such registration statement or prospectus, furnish a copy thereof to each seller of such Registrable Shares; and

 

(h)at
the request of any seller of such Registrable Shares in connection with an underwritten offering, furnish on the date or dates
provided for in the underwriting agreement: (i) an opinion of counsel, addressed to the underwriters and the sellers of Registrable
Shares, covering such matters as such underwriters and sellers may reasonably request, including such matters as are customarily
furnished in connection with an underwritten offering; (ii) a letter or letters from the independent certified public accountants
of the Company addressed to the underwriters and the sellers of Registrable Shares, covering such matters as such underwriters
and sellers may reasonably request, in which letter(s) such accountants shall state, without limiting the generality of the foregoing,
that they are independent certified public accountants within the meaning of the Securities Act and that in their opinion the financial
statements and other financial data of the Company included in the registration statement, the prospectus(es), or any amendment
or supplement thereto, comply in all material respects with the applicable accounting requirements of the Securities Act; and (iii)
officers or employees for participation in the “road shows” for such underwritten offering provided that the Stockholders
shall be required to pay the costs of such items.

 

    	5

    	 

    

 

6.Registration
Expenses.

 

6.1Company’s
Expenses. All expenses incident to the Company’s performance of or compliance with this Agreement, including without
limitation all registration and filing fees, fees and expenses of compliance with securities laws, printing expenses, messenger
and delivery expenses, and fees and disbursements of counsel for the Company and all independent certified public accountants (including
all special audit and financial statement costs), and other persons retained by the Company (all such expenses being herein called
“Registration Expenses”), will be borne by the Company.

6.2Holder’s
Expenses. Notwithstanding anything to the contrary contained herein, each holder of Registrable Shares will pay all discounts
and commissions attributable to their respective shares and all attorney fees and disbursements for counsel they retain in connection
with the registration of Registrable Shares, as the case may be.

 

7.Indemnification.

7.1By
the Company. The Company agrees to indemnify, to the extent permitted by law, each holder of Registrable Shares, its officers,
directors and trustees and each person who controls such holder (within the meaning of the Securities Act) against all losses,
claims, damages, liabilities and expenses (including without limitation, attorney’s fees) caused by or relating to any action
or proceeding arising out of or based upon any untrue or alleged untrue statement of material fact contained in any registration
statement, prospectus or preliminary prospectus, or any amendment thereof or supplement thereto, or any omission or alleged omission
of a material fact required to be stated therein or necessary to make the statements therein not misleading, except such indemnification
shall not be available to a holder, its officers and directors or controlling person insofar as the same are caused by or contained
in any information furnished in writing to the Company by such holder expressly for use therein or by such holder’s failure
to deliver a copy of the registration statement or prospectus or any amendments or supplements thereto. In connection with an underwritten
offering, the Company will indemnify such underwriters, their officers and directors and each person who controls such underwriters
(within the meaning of the Securities Act) to the same extent as provided above with respect to the indemnification of the holders
of Registrable Shares. The payments required by this Section 7.1 will be made periodically during the course of the investigation
or defense, as and when bills are received or expenses incurred.

 

7.2By
Each Holder. In connection with any registration statement in which a holder of Registrable Shares is participating, each such
holder will furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection
with any such registration statement or prospectus and, to the extent permitted by law, will indemnify the Company, its directors
and officers and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages,
liabilities and expenses resulting from any untrue or alleged untrue statement of material fact contained in the registration statement,
prospectus or preliminary prospectus, or any amendment thereof or supplement thereto, or any omission or alleged omission of a
material fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent
that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such holder; provided
that the obligation to indemnify will be several, not joint and several, among such holders of Registrable Shares and the liability
of each such holder of Registrable Shares will be limited to and in proportion to the net amount received by such holder from the
sale of Registrable Shares, as the case may be, pursuant to such registration statement.

 

    	6

    	 

    

 

7.3Procedure.
Any person entitled to indemnification hereunder will (a) give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification (failure of any indemnified party to give notice as provided herein shall not relieve
the indemnifying party of its obligations hereunder, except to the extent that the indemnifying party is prejudiced by the failure
to give such notice), and (b) unless in such indemnified party’s reasonable judgment a conflict of interest between such
indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party. After notice from the indemnifying party to such
indemnified party of its election so to assume the defense thereof, the indemnifying party will not be subject to any liability
for any settlement made by the indemnified party without its consent (but such consent will not be unreasonably withheld). An
indemnifying party who is not entitled to, or elects not to, assume the defense of a claim will not be obligated to pay the fees
and expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless
in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other
of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party,
consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money
(and such money is so paid by the indemnifying party pursuant to the terms of such settlement) and which settlement does not include
as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability
in respect to such claim or litigation.

 

7.4 Contribution.
If the indemnification provided for in this Section 7 from the indemnifying party is unavailable to an indemnified party
hereunder in respect of any losses, claims, damages, liabilities or expenses to which such indemnified party would be otherwise
entitled under Section 7, then the indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the
amount paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses in such
proportion as is appropriate to reflect the relative fault of the indemnifying party and indemnified parties in connection with
the actions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.
The relative fault of such indemnifying party and indemnified parties shall be determined by reference to, among other things,
whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission
to state a material fact, has been made by, or relates to information supplied by, such indemnifying party or indemnified parties,
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action. The
amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall
be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with any investigation
or proceeding. In no event shall any person be required to contribute an amount greater than the dollar amount of the proceeds
received by such person with respect to the sale of any Registrable Shares.

 

The parties hereto agree that it would not be
just and equitable if contribution pursuant to this Section 7.4 were determined by pro rata allocation or by any other method
of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation. The contribution provided for in this
Section 7.4 shall remain in full force and effect regardless of any investigation made by or on behalf of any indemnified party.

 

    	7

    	 

    

 

7.5Survival.
The indemnification provided for under this Agreement will remain in full force and effect regardless of any investigation made
by or on behalf of the indemnified party or any officer, director, trustee or controlling person of such indemnified party and
will survive the transfer of securities. The Company also agrees to make such provisions as are reasonably requested by any indemnified
party for contribution to such party in the event the Company’s indemnification is unavailable for any reason.

 

8.Compliance
with Rule 144. In the event that the Company (a) registers a class of securities under Section 12 of the Exchange Act, (b)
issues an offering circular meeting the requirements of Regulation A under the Securities Act or (c) commences to file reports
under Section 13 or 15(d) of the Exchange Act, then at the request of any holder who proposes to sell securities in compliance
with Rule 144 of the Commission, the Company will (i) forthwith furnish to such holder a written statement of compliance with the
filing requirements of the Commission as set forth in Rule 144, as such rule may be amended from time to time and (ii) make available
to the public and such holders such information as will enable the holders to make sales pursuant to Rule 144.

 

9.Participation
in Underwritten Registrations. No person may participate in any registration hereunder which is underwritten unless such person
(a) agrees to sell its securities on the basis provided in any underwriting arrangements approved by such person or persons entitled
hereunder to approve such arrangements, (b) completes and executes all customary questionnaires, powers of attorney, custody agreements,
indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements,
(c) provides all customary information reasonably requested by the Company or underwriter in connection with such registration,
including copies of customary documents, instruments and agreements and (d) complies with all applicable federal and state securities
laws in connection with such registration.

 

10.Miscellaneous.

 

10.1Successors
and Assigns. This Agreement is not assignable by any Stockholder without the express written consent of the Company. Except
as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the
parties hereto will bind and inure to the benefit of the respective successors and assigns of the parties hereto, whether so expressed
or not. In addition, and whether or not any express assignment has been made, the provisions of this Agreement which are for the
benefit of holders of Registrable Shares are also for the benefit of, and enforceable by, any subsequent holders of such Shares.

 

    	8

    	 

    

 

10.2Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be
ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

10.3Descriptive
Headings. The descriptive headings of this Agreement are inserted for convenience of reference only and do not constitute
a part of and shall not be utilized in interpreting this Agreement.

 

10.4Notices.
Any notices and other communications hereunder shall be in writing and shall be deemed given and received (i) on the date of delivery
if delivered personally, (ii) on the date of confirmation of receipt (or, the first Business Day following such receipt if the
date is not a Business Day) if delivered by a nationally recognized overnight courier service (providing written proof of delivery),
such as Federal Express, (iii) on the date of confirmation of receipt (or, the first Business Day following receipt if the date
is not a Business Day) if sent via facsimile to the parties hereto at the following address, or at such other address for a party
as shall be specified by like notice, provided that a notice of change in address shall not be deemed to have been given until
received by the addressee:

 

	If to the Company, to:	 	 	 
		 	Bone Biologics, Corp.	 
	 	 	175 May Street, Suite 400	 
	 	 	Edison, NJ 08837	 
	 	 	Attention:  Michael Schuler	 
	 	 	Facsimile No.:  (732) 661-2152	 
	 	 	Telephone No.:  (732) 661-2589	 
	 	 	 	 
	 	with a copy (which shall not constitute notice) to:	 
	 	 	 	 
	 	 	DLA Piper LLP (US)	 
	 	 	550 S. Hope Street	 
	 	 	Los Angeles, CA 90071	 
	 	 	Attention:  Ann Lawrence	 
	 	 	Facsimile:  (213) 330-7555	 
	 	 	Telephone:  (213) 330-7755	 

    	9

    	 

    

 

	If to the AFH, to:	 	AFH Holding and Advisory, LLC	 
	 	 	4751 Wilshire Blvd., Suite 110	 
	 	 	Los Angeles, CA 90010	 
	 	 	Attention:  Eugene Leydiker	 
	 	 	Facsimile No.:  (323) 692-4126	 
	 	 	Telephone No.:  (323) 692-4026	 
	 	 	 	 
	 	with a copy (which shall not constitute notice) to:	 
	 	 	 	 
	 	 	Reed Smith LLP	 
	 	 	599 Lexington Avenue	 
	 	 	New York, N.Y. 10022	 
	 	 	Attention:  Bill Haddad	 
	 	 	Facsimile No.:  (212) 521-5450	 
	 	 	Telephone No.:  (212) 549-0379	 
	 	 	 	 
	If to the MTF, to:	 	 	 
	 	 	Musculoskeletal Transplant Foundation	 
	 	 	125 May Street	 
	 	 	Edison, NJ 08837	 
	 	 	Attention: Bruce Stroever, President, CEO	 
	 	 	Facsimile No.: (732) 661-2297	 
	 	 	Telephone No.:  (732) 661-0202	 

 

10.5Governing
Law. All questions concerning the construction, validity and interpretation of this Agreement, and the performance of the
obligations imposed by this Agreement, shall be governed by the laws of the State of Delaware applicable to contracts made and
wholly to be performed in that state.

 

10.6Final
Agreement. This Agreement, together with the Merger and all other agreements entered into by the parties hereto, constitutes
the complete and final agreement of the parties concerning the matters referred to herein, and supersedes all prior agreements
and understandings.

 

10.7Execution
in Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered
shall be deemed an original, and such counterparts together shall constitute one instrument.

 

10.8No Strict
Construction. The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express
their mutual intent, regardless of which party drafted this Agreement.

 

    	10

    	 

    

 

10.9Amendment.
Except as otherwise expressly provided herein, the provisions of this Agreement may be amended or waived at any time only by the
written agreement of the Company, MTF and AFH. Any waiver, permit, consent or approval of any kind or character on the part of
any such holder of any provisions or conditions of this Agreement must be made in writing and shall be effective only to the extent
specifically set forth in such writing.

 

10.10Waiver
of Jury Trial. Each of the parties hereto hereby irrevocably waives any and all right to trial by jury of any claim or cause
of action in any legal proceeding arising out of or related to this Agreement or the transactions or events contemplated hereby
or any course of conduct, course of dealing, statements (whether verbal or written) or actions of any party hereto. The parties
hereto each agree that any and all such claims and causes of action shall be tried by a court trial without a jury. Each of the
parties hereto further waives any right to seek to consolidate any such legal proceeding in which a jury trial has been waived
with any other legal proceeding in which a jury trial cannot or has not been waived.

 

[The Rest of this Page
Intentionally Left Blank]

 

    	11

    	 

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Registration Rights Agreement on the date first set forth above.

 

	 	BONE BIOLOGICS, CORP.
	 	 	 
	 	By:	/s/
    Michael Schuler
	 	Name:	Michael Schuler
	 	Its:	Chief Executive Officer and Director
	 	 	 
	 	AFH HOLDING AND ADVISORY, LLC
	 	 	 
	 	By:	/s/
    Amir F. Heshmatpour
	 	Name:	Amir F. Heshmatpour
	 	Its:	Managing Director
	 	 	 
	 	THE MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
	 	 	 
	 	By:	/s/
    Michael J. Kawas
	 	Name:	Michael J. Kawas
	 	Its:	Executive Vice President and Chief Financial Officer

 

    	12BONE
BIOLOGICS, CORP.

 

CONVERTIBLE
NOTE PURCHASE AGREEMENT

 

This
Convertible Note Purchase Agreement (the “Agreement”) is made as of the 19th day of September 2014, by and
between Bone Biologics, Corp., a Delaware corporation (the “Company”), and Musculoskeletal Transplant Foundation,
Inc., a District of Columbia non- profit corporation (“MTF”).

 

RECITALS

 

A.
The Company and MTF have a strategic business relationship to address various matters of mutual interest. In furtherance thereof,
the Company and MTF have from time to time entered into transactions pursuant to which MTF has supported the Company’s product
development activities and the Company has established MTF as the exclusive supplier to the Company of human allograft tissue.

 

B.
As the parties continue discussions for a broader relationship, MTF has made available a loan to the Company, which the Company
intends to use to support the Company’s product development activities, including, without limitation, protein development
and production and animal trials, consistent with the Company’s ongoing development plans.

 

C.
To memorialize and evidence the funds loaned by MTF to the Company, the Company desires to issue and sell to MTF, and MTF desires
to purchase, a convertible promissory note in the form attached to this Agreement as Exhibit A (the “Note”),
which shall be convertible on the terms stated therein into shares of Common Stock (as hereinafter defined) of the Company.

 

AGREEMENT

 

In
consideration of the mutual promises contained herein and other good and valuable consideration, receipt of which is hereby acknowledged,
the parties to this Agreement agree as follows:

 

1.
Definitions. As used herein, the following terms shall have the following respective meanings:

 

(a)
“Accessions”
shall have the meaning given that term in the UCC.

 

(b)
“Account”
shall have the meaning given that term in the UCC.

 

(c)
“Account
Debtor” shall
have the meaning given that term in the UCC.

 

(d)
“AFH”
shall have the meaning set forth in Section 2(a) hereof.

 

(e)
 “Agreement”
shall have the meaning set forth in the preamble hereto.

 

(f)
“BBI”
shall have the meaning set forth in Section 2(a) hereof.

 

    	 

    	 

    

 

(g)
“Chattel Paper” shall have the meaning given that term in the UCC. 

 

(h)
“Collateral” shall mean all personal property of the Company, including, without limitation, all: (a) Accounts,
(b) Chattel Paper, (c) Commercial Tort Claims, (d) Deposit Accounts, (e) Documents, (f) Equipment, (g) Fixtures, (h) General Intangibles
(including Payment Intangibles), (i) Goods, (j) Instruments, (k) Inventory, (l) Investment Property, (m) Letter-of-Credit Rights,
(n) Software, (o) Supporting Obligations, (p) money, policies and certificates of insurance, deposits, cash, cash equivalents,
or other property, (q) all books, records, and information relating to any of the foregoing ((a) through (p)) and/or the Company’s
business, and all rights of access to such books, records, and information, and all property in which such books, records, and
information are stored, recorded and maintained, all insurance proceeds, refunds, and premium rebates, including, without limitation,
proceeds of fire and credit insurance, whether any of such proceeds, refunds, and premium rebates arise out of any of the foregoing
((a) through (q)) or otherwise, (s) all Liens, guaranties, rights, remedies, and privileges pertaining to any of the foregoing
((a) through (r)), including the right of stoppage in transit, and (t) any of the foregoing, whether now owned or now due, in
which the Company has an interest, or hereafter acquired, arising, or to become due, in which the Company obtains an interest,
and all products, Proceeds, substitutions, and Accessions of or to any of the foregoing; provided, however, that the Collateral
shall not include, and the security interest shall not attach to, any Excluded Property. 

 

(i)
“Commercial
Tort Claim” shall
have the meaning given that term in the UCC.

 

(j)
“Common Stock”
shall have the meaning set forth in the Section 7(d) hereof.

 

(k)
“Company”
shall have the meaning set forth in the preamble hereto.

 

(l)
“Copyright
Licenses” shall
mean any and all agreements providing for the granting of any right in or to Copyrights (whether the Company is licensee or licensor
thereunder).

 

(m)
“Copyrights”
shall mean all United States and foreign copyrights (including
community designs), including but not limited to copyrights in software and databases, and all Mask Works (as defined under 17
U.S.C. 901 of the U.S. Copyright Act), whether registered or unregistered, and, with respect to any and all of the foregoing:
(i) all registrations and applications therefor, (ii) all extensions and renewals thereof, (iii) all rights corresponding thereto
throughout the world, (iv) all rights to sue for past, present and future infringements thereof, and (v) all Proceeds of the foregoing,
including, without limitation, licenses, royalties, income, payments, claims, damages and proceeds of suit.

 

(n)
“Credit Agreement”
shall have the
meaning set forth in the Section 3(c) hereof.

 

    	2

    	 

    

 

(o)
“Deposit
Account” shall
have the meaning given that term in the UCC and shall also include all demand, time, savings, passbook, or similar accounts maintained
with a bank or other financial institution.

 

(p)
“Documents”
shall have the meaning given that term in the UCC.

 

(q)
“Equipment”
shall mean “equipment”, as defined in the UCC,
and shall also mean all furniture, store fixtures, motor vehicles, rolling stock, machinery, office equipment, plant equipment,
tools, dies, molds, and other goods, property, and assets which are used and/or were purchased for use in the operation or furtherance
of the Company’s business, and any and all Accessions or additions thereto, and substitutions therefor.

 

(r)
“Equity Securities”
shall have the meaning
set forth in the Section 7(a) hereof.

 

(s)
“Exclusivity Period”
shall have the meaning set forth in the Section 9(a) hereof.

 

(t)
“Field”
shall have the meaning set forth in the Section 9(a) hereof.

 

(u)
“Fixtures”
shall have the meaning given that term in the UCC.

 

(v)
“General Intangibles” shall have the meaning given that term in
the UCC., and shall also include, without limitation, all: Payment Intangibles; rights to payment for credit extended; deposits;
amounts due to the Company; credit memoranda in favor of the Company; warranty claims; tax refunds and abatements; insurance refunds
and premium rebates; all means and vehicles of investment or hedging, including, without limitation, options, warrants, and futures
contracts; records; customer lists; telephone numbers; goodwill; causes of action; judgments; rights to collect payments under
any settlement or other agreement; literary rights; rights to performance; royalties; license and/or franchise fees; rights of
admission; licenses; franchises; license agreements, including all rights of the Company to enforce same; permits, certificates
of convenience and necessity, and similar rights granted by any governmental authority; developmental ideas and concepts; proprietary
processes; blueprints, drawings, designs, diagrams, plans, reports, and charts; catalogs; technical data; tapes, disks, semi-conductors
chips and printouts; Intellectual Property; proposals; cost estimates, and reproductions on paper, or otherwise, of any and all
concepts or ideas, and any matter related to, or connected with, the design, development, manufacture, sale, marketing, leasing,
or use of any or all property produced, sold, or leased, by or credit extended or services performed, by the Company, whether
intended for an individual customer or the general business of the Company, or used or useful in connection with research by the
Company.

 

(w)
“Goods”
shall have the meaning given that term in the UCC.

 

(x)
“Instruments”
shall have the meaning given that term in the UCC.

 

    	3

    	 

    

 

(y)
“Intellectual
Property” shall
mean, collectively, the Copyrights, the Copyright Licenses, the Patents, the Patent Licenses, the Trademarks, the Trademark Licenses,
the Trade Secrets, and the Trade Secret Licenses.

 

(z)
“Inventory”
shall have the meaning given that term in the UCC, and shall
also include, without limitation, all: (a) Goods which (i) are leased by a person as lessor, (ii) are held by a person for sale
or lease or to be furnished under a contract of service, (iii) are furnished by a person under a contract of service, or (iv)
consist of raw materials, work in process, or materials used or consumed in a business; (b) Goods of said description in transit;
(c) Goods of said description which are returned, repossessed or rejected; and (d) packaging, advertising, and shipping materials
related to any of the foregoing.

 

(aa)
“Investment
Property” shall
have the meaning given that term in the UCC.

 

(bb)
“Letter-of-Credit
Right” shall
have the meaning given that term in the UCC and shall also mean any right to payment or performance under a letter of credit,
whether or not the beneficiary has demanded, or is at the time entitled to demand, payment or performance.

 

(cc)
“Lien”
shall mean any lien, mortgage, pledge, assignment, security
interest, charge or encumbrance of any kind (including any agreement to give any of the foregoing, any conditional sale or other
title retention agreement, and any lease in the nature thereof) and any option, trust or other preferential arrangement having
the practical effect of any of the foregoing.

 

(dd)
“Loan Agreement”
shall have the meaning set forth in the Section 3(b) hereof.

 

(ee)
“Merger”
shall have the meaning set forth in Section 2(a) hereof.

 

(ff)
“Merger
Agreement” shall
have the meaning set forth in Section 2(a) hereof.

 

(gg)
“Merger
Sub” shall have
the meaning set forth in Section 2(a) hereof.

 

(hh)
“MTF”
shall have the meaning set forth in the preamble hereto.

 

(ii)
“MTF Distributorship Agreement”
shall have the meaning set forth in the Section 9(b) hereof.

 

(jj)
“Note”
shall have the meaning set forth in the recitals
hereto.

 

(kk)
“Patent
Licenses” shall
mean all agreements providing for the granting of any right in or to Patents (whether the Company is licensee or licensor thereunder).

 

    	4

    	 

    

 

(ll)
“Patents”
shall mean all United States and foreign patents and certificates
of invention, or similar industrial property rights, and applications therefore, including, but not limited to: (i) each patent
and patent application set forth on Schedule 1 attached hereto, (ii) each patent and patent application related thereto, (iii)
all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iv) all rights
corresponding thereto throughout the world, (v) all inventions and improvements described therein, (vi) all rights to sue for
past, present and future infringements thereof, (vii) all licenses, claims, damages, and proceeds of suit arising therefrom, and
(ix) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages, and
proceeds of suit.

 

(mm)
“Payment
Intangible” shall
have the meaning given that term in the UCC and shall also mean any General Intangible under which the Account Debtor’s
primary obligation is a monetary obligation.

 

(nn)
“Preferred Stock”
shall have the meaning set forth in the Section 7(d) hereof.

 

(oo)
“Prior Notes”
shall have the meaning
set forth in the Section 2(b) hereof.

 

(pp)
“Proceeds”
shall mean: (i) all “proceeds” as defined in
Article 9 of the UCC, and (ii) whatever is receivable or received when Collateral or proceeds are sold, exchanged, collected or
otherwise disposed of, whether such disposition is voluntary or involuntary.

 

(qq)
“Product”
shall have the meaning set forth in the Section 9(a) hereof.

 

(rr)
“Related Documents”
shall have the meaning set forth in the Section 3(d) hereof.

 

(ss)
“Securities” shall mean the Note and shares of the Common Stock issuable upon conversion thereof (and the securities
issuable upon conversion of such shares of Common Stock).

 

(tt)
“Securities Act”
shall have the meaning
set forth in the Section 7(a) hereof.

 

(uu)
“Software”
shall have the meaning given that term in the UCC.

 

(vv)
“Supporting
Obligation” shall
have the meaning given that term in the UCC and shall also refer to a Letter-of-Credit Right or secondary obligation that supports
the payment or performance of an Account, Chattel Paper, a Document, a General Intangible, an Instrument, or Investment Property.

 

(ww)
“Trademark
Licenses” shall
mean any and all agreements providing for the granting of any right in or to Trademarks, irrespective of whether the Company is
licensee or licensor thereunder.

 

    	5

    	 

    

 

(xx)
“Trademarks”
shall mean all United States, and foreign trademarks, trade
names, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification
marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, and all
registrations and applications therefore for any of the foregoing including, but not limited to: (i) the registrations and applications
set forth on Schedule 1 attached hereto (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of
the business connected with the use of and symbolized by the foregoing, (iv) the right to sue for past, present and future infringement
or dilution of any of the foregoing or for any injury to goodwill, and (v) all Proceeds of the foregoing, including, without limitation,
licenses, royalties, income, payments, claims, damages, and proceeds of suit.

 

(yy)
“Trade
Secret Licenses”
shall mean any and all agreements providing for the granting of any right in or to Trade Secrets, irrespective of whether the
Company is licensee or licensor thereunder.

 

(zz)
“Trade
Secrets” shall
mean all trade secrets and all other confidential or proprietary information and know-how whether or not such Trade Secret has
been reduced to a writing or other tangible form, including all documents and things embodying, incorporating, or referring in
any way to such Trade Secret, including but not limited to: (i) the right to sue for past, present and future misappropriation
or other violation of any Trade Secret, and (ii) all Proceeds of the foregoing, including, without limitation, licenses, royalties,
income, payments, claims, damages, and proceeds of suit.

 

(aaa)
 “UCC”
shall mean the Uniform Commercial Code as from time to time
in effect in the State of New Jersey; provided, however, that, in the event that, by reason of mandatory provisions of law, any
of the attachment, perfection or priority of MTF’s and MTF’s security interest in any Collateral is governed by the
Uniform Commercial Code as in effect in a jurisdiction other than the State of New Jersey, the term
“UCC” shall mean
the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such attachment,
perfection or priority and for purposes of definitions related to such provisions.

 

2.
Condition Precedent.

 

(a)
On September 19, 2014, AFH Acquisition X, Inc. (“AFH”) and its wholly-owned subsidiary, Bone Biologics Acquisition
Corp. (“Merger Sub”) entered into an Agreement and Plan of Merger, dated September 19, 2014 (“Merger
Agreement”), by and among AFH, Bone Biologics, Inc. (“BBI”) and Merger Sub. Pursuant to the terms
of the Merger Agreement, BBI intends to merge with Merger Sub, with BBI as the surviving entity (“Merger”).
After the Merger, AFH shall cease to be a shell company, as defined in the rules of the Securities and Exchange Commission, and
AFH will officially change its name to “Bone Biologics, Corp.”

 

(b)
This Agreement shall become effective only upon surrender by MTF of the certain (i) Promissory Note issued by BBI to MTF, dated
as of November 4, 2008, in the face amount of $250,000; (ii) Promissory Note issued by BBI to MTF, dated as of March 16, 2009,
in the face amount of $400,000; (iii) Promissory Note issued by BBI to MTF, dated as of August 24, 2009, in the face amount of
$16,420; and (iv) Tranched Promissory Note issued by BBI to MTF, dated as of September 30, 2009, in the face amount of $445,400,
each as may have been amended from time to time (collectively, the “Prior Notes”).

 

    	6

    	 

    

 

3.
Cancelation of Prior Notes; Termination of Other Agreements. Should the condition precedent set forth in Section
2(b) not occur on or before September 20, 2014, this Agreement shall be null and void and the Prior Notes shall be promptly returned
to MTF. Notwithstanding the foregoing, upon the occurrence of the condition precedent set forth in Section 2:

 

(a)
the Prior Notes shall be canceled, null, void and of no further effect;

 

(b)
the certain Loan Agreement, dated as of November 4, 2008, between MTF and BBI, as may have been amended from time to time (the
“Loan Agreement”), shall be terminated, null, void and of no further effect;

 

(c)
the certain Credit Agreement, dated as of March 17, 2009, between MTF and BBI, as may have been amended from time to time (the
“Credit Agreement”), shall be terminated, null, void and of no further effect; and

 

(d)
all documents and agreements issued in connection with the Loan Agreement and Credit Agreement, including, without limitation,
guarantees, each as may have been amended from time to time (the “Related Documents”), shall be terminated,
null, void and of no further effect.

 

4.
Issuance of Note. In consideration for cancelation of the Prior Notes and termination of the Loan Agreement, Credit
Agreement and Related Documents, subject to the terms and conditions of this Agreement, the Company shall contemporaneously herewith
execute and deliver the Note to MTF, in the aggregate principal amount of Three Million Six Hundred Fifty Nine Thousand Three
Hundred and Twenty Eight Dollars ($3,659,328), which such amount shall be adjusted as set forth in the Note.

 

5.
Grant of Security.

 

(a)
Grant of Security. The Company hereby grants to MTF a security interest in and continuing lien on all of the Company’s
right, title and interest in, to and under the Collateral.

 

(b)
Certain Limited Exclusions. Notwithstanding anything herein to the contrary, in no event shall the Collateral include
or the security interest granted under Section 5(a) hereof attach to: any lease, license, contract, property rights or agreement
to which the Company is a party or any of its rights or interests thereunder if and for so long as the grant of such security
interest shall constitute or result in (i) the abandonment, invalidation or unenforceability of any right, title or interest of
the Company therein or (ii) in a breach or termination pursuant to the terms of, or a default under, any such lease, license,
contract, property right or agreement (other than to the extent that any such term would be rendered ineffective pursuant to Sections
9-406, 9-407, 9-408 or 9-409 of the UCC (as defined herein) (or any successor provision or provisions) of any relevant jurisdiction
or any applicable law (including the Bankruptcy Code) or principles of equity), provided however that the Collateral shall include
and such security interest shall attach immediately at such time as the condition causing such abandonment, invalidation or unenforceability
shall be remedied and to the extent severable, shall attach immediately to any portion of such lease, license, contract, property
rights or agreement that does not result in any of the consequences specified in (i) or (ii) above.

 

    	7

    	 

    

 

6.
Security for Obligations; the Company Remains Liable.

 

(a)
Security for Obligations. This Agreement secures, and the Collateral is collateral security for, the prompt
and complete payment or performance in full when due, whether at stated maturity, by required prepayment, declaration, acceleration,
demand or otherwise (including the payment of amounts that would become due but for the operation of the automatic stay under
section 362(a) of the Bankruptcy Code, 11 U.S.C. §362(a) (any successor provision thereof)) with respect to the Company.

 

(b)
Continuing Liability Under Collateral. Notwithstanding anything herein to the contrary, (i) the Company shall
remain liable for all obligations under the Collateral and nothing contained herein is intended or shall be a delegation of duties
to MTF, (ii) the Company shall remain liable under each of the agreements included in the Collateral, to perform all of the obligations
undertaken by it thereunder all in accordance with and pursuant to the terms and provisions thereof and MTF shall not have any
obligation or liability under any of such agreements by reason of or arising out of this Agreement or any other document related
thereto nor shall MTF have any obligation to make any inquiry as to the nature or sufficiency of any payment received by it or
have any obligation to take any action to collect or enforce any rights under any agreement included in the Collateral, and (iii)
the exercise by MTF of any of its rights hereunder shall not release the Company from any of its duties or obligations under the
contracts and agreements included in the Collateral.

 

7.
Representations and Warranties of the Company. The Company hereby represents and warrants to MTF that:

 

(a)
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business
as now conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in
each jurisdiction in which the failure so to qualify would have a material adverse effect on its business or properties. For purposes
hereof, “Equity Securities” shall have the meaning set forth under Rule 405 (or any successor rule) promulgated
by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the “Securities Act”).

 

    	8

    	 

    

 

(b)
Authorization. All corporate action on the part of the Company, its officers, directors and shareholders necessary
for the authorization, execution and delivery of this Agreement and the authorization, sale, issuance and delivery of the Note
(and of the Securities issuable, respectively, upon conversion of the Note and of the shares of Common Stock issuable upon such
conversion), and the performance of all obligations of the Company under this Agreement and the Note has been taken, including,
without limitation, the approval by the directors and shareholders of the Company. The Agreement and the Note, when executed and
delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company
in accordance with their respective terms except as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights generally, and as
limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

(c)
Conflicts. Neither the execution and delivery of this Agreement or the Note, nor the consummation of the transactions
contemplated in this Agreement or the Note, will violate any provision of the certificate of incorporation or by-laws of the Company
or any law, rule, regulation, writ, judgment, injunction, decree, determination, award or other order of any court, government,
or governmental agency or instrumentality, domestic or foreign, binding upon the Company, or conflict with or result in any breach
of or event of termination under any of the terms of, or the creation or imposition of any mortgage, deed of trust, pledge, lien,
security interest or other charge or encumbrance of any nature pursuant to, the terms of any contract or agreement to which the
Company is a party or by which the Company or any of its properties or assets is bound.

 

(d)
Capitalization. The Articles of Incorporation of the Company have been duly filed with the Secretary of State of
Delaware. The authorized capital stock of the Company consists of 100,000,000 shares of common stock, $0.001 par value (“Common
Stock”) and 20,000,000 shares of preferred stock, $0.001 par value (“Preferred Stock”). All of the
outstanding shares of Common Stock and Preferred Stock have been validly issued and are fully-paid and non-assessable; and the
shares of Common Stock issuable upon conversion of the Note, when issued and delivered upon such conversion, will be validly issued,
fully-paid and non-assessable shares of Common Stock, in each case free and clear of any mortgages, deed of trust, pledge, lien,
security interest or any charge or encumbrance of any nature. There are no contracts, agreements, arrangements (written or oral)
or other documents to which the Company is a party regulating or controlling or otherwise affecting the voting or disposition
of any shares of stock of the Company, or the management thereof.

 

(e)
Operations. The Company is not the subject of any material claim, suit or proceeding before any court or governmental
agency and is not delinquent in any material respects in the payment of any taxes or is in violation in any material respect of
any law, rule or regulation.

 

(f)
Intellectual Property. The Company owns, or is licensed or has the rights necessary to use, or is negotiating to
license or obtain the rights to use, all intellectual property material to its business as proposed to be conducted.

 

    	9

    	 

    

 

(g)
Disclosure. No representation or warranty made under any provisions hereof, and none of the information furnished
by the Company to MTF, or any authorized representative of MTF, contains any untrue statement of a material fact or omits to state
a material fact necessary to make the statements herein or therein not misleading.

 

8.
Representations and Warranties of MTF. MTF hereby represents and warrants to the Company that:

 

(a)
Authorization. MTF has full power and authority to enter into this Agreement. This Agreement, when executed and
delivered by MTF, will constitute a valid and legally binding obligation of MTF, enforceable in accordance with its terms, except
as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general
application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of
a specific performance, injunctive relief, or other equitable remedies.

 

(b)
Purchase Entirely for Own Account. This Agreement is made with MTF in reliance upon MTF’s representation to
the Company, which by MTF’s execution of this Agreement, MTF hereby confirms, that the Securities to be acquired by MTF
will be acquired for investment for MTF’s own account, not as a nominee or agent, and not with a view to the resale or distribution
of any part thereof, and that MTF has no present intention of selling, granting any participation in, or otherwise distributing
the same. By executing this Agreement, MTF further represents that MTF does not presently have any contract, undertaking, agreement
or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to
any of the Securities. MTF has not been formed for the specific purpose of acquiring any of the Securities.

 

(c)
Knowledge. MTF is aware of the Company’s business affairs and financial condition and has acquired sufficient
information about the Company to reach an informed and knowledgeable decision to acquire the Note.

 

(d)
Restricted Securities. MTF understands that the Securities have not been, and will not be, registered under the
Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of MTF’s representations as expressed herein.
MTF understands that the Securities are “restricted securities” under applicable U.S. federal and state securities
laws and that, pursuant to these laws, MTF must hold the Securities indefinitely unless they are registered with the Securities
and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements
is available. MTF acknowledges that the Company has no obligation to register or qualify the Securities for resale. MTF further
acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating
to the Company which are outside of MTF’s control, and which the Company is under no obligation and may not be able to satisfy.

 

    	10

    	 

    

 

(e)
No Public Market. MTF understands that no public market now exists for any of the securities issued by the Company,
that the Company has made no assurances that a public market will ever exist for the Securities. 

 

(f)
Legends. MTF understands that the Securities, and any securities issued in respect thereof or exchange therefor,
may bear one or all of the following legends:

 

(i)
“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN
ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION
MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

 

(ii)
Any legend required by the Blue Sky laws of any state to the extent such laws are applicable to the shares represented by the
certificate so legended.

 

(g)
Accredited Investor. MTF is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act.

 

9.
Distribution Rights.

 

(a)
From and after the date hereof and until the satisfaction in full or conversion of the entire principal amount of the Note (and
all interest accrued thereon) in accordance with the terms of the Note (subject to extension as hereinafter set forth, the “Exclusivity
Period”), the Company shall not, directly or indirectly (itself or through any other person or entity), whether as principal,
agent, distributor, representative, stockholder or otherwise, distribute or provide any invention, device, instrument, apparatus
and/or other product or service (collectively, a “Product”) with application in the field of spine surgery
(the “Field”), worldwide or in any territory thereof, except pursuant to the terms and provisions of an MTF
Distributorship Agreement (as hereinafter defined). If an Event of Default (as defined in the Note) shall at any time occur, the
Exclusivity Period shall automatically be extended through the period that expires on the tenth anniversary of the date of this
Agreement.

 

(b)
In the event that, during the Exclusivity Period, the Company desires to distribute any Product in the Field, the Company shall
deliver written notice thereof to MTF, which shall set forth with particularity the design, use and status of such Product and
shall, when applicable, enclose a prototype. MTF shall, within 60 days of receipt of such notice, submit to the Company a proposal
for an exclusive, worldwide distributorship arrangement (each, an “MTF Distributorship Agreement”) with respect
to such Product for applications within the Field, whereupon the parties shall collaborate with each other in good faith so as
to complete arrangements reasonably acceptable to each whereby MTF shall exclusively distribute such Product, worldwide, for applications
within the Field.

 

    	11

    	 

    

 

10.
Miscellaneous.

 

(a)
Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding
upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(b)
Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the
parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving
effect to principles of conflicts of law.

 

(c)
Counterparts. This Agreement may be executed in two or more counter-parts, each of which shall be deemed an original
and all of which together shall constitute one instrument.

 

(d)
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not
to be considered in construing or interpreting this Agreement.

 

(e)
Notices. Any notice required or permitted by this Agreement or the Note shall be in writing and shall be deemed
sufficient upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or 48 hours
after being deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the
party to be notified at such party’s address or facsimile number as set forth below or as subsequently modified by written
notice.

 

(f)
Finder’s Fee. Each party represents that it neither is nor will be obligated for any finder’s fee or
commission in connection with this transaction. MTF agrees to indemnify and to hold harmless the Company from any liability for
any commission or compensation in the nature of a finder’s fee (and the costs and expenses of defending against such liability
or asserted liability) for which MTF or any of its officers, employees, or representatives is responsible. The Company agrees
to indemnify and hold harmless MTF from any liability for any commission or compensation in the nature of a finder’s fee
(and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers,
employees or representatives is responsible.

 

(g)
Amendments and Waivers. Any term of this Agreement may be amended or waived only with the written consent of the
Company and MTF. Any amendment or waiver effected in accordance with this Section 10(g) shall be binding upon MTF and the Company,
and their respective successors and assigns.

 

    	12

    	 

    

 

(h)
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the
parties agree to renegotiate such provision in good faith, in order to maintain the economic position enjoyed by each party as
close as possible to that under the provision rendered unenforceable. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance
of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable
in accordance with its terms.

 

(i)
Entire Agreement. This Agreement, and the documents referred to herein constitute the entire agreement between the
parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements existing between the
parties hereto are expressly canceled.

 

(j)
Shareholders, Officers and Directors Not Liable. In no event shall any shareholder, officer or director of the Company
be liable for any amounts due or payable pursuant to the Note.

 

(k)
Survival of Representations. Each representation, warranty, covenant and agreement of the parties hereto herein
contained shall survive the execution and delivery of this Agreement and the Note, and the satisfaction or conversion of the Note
or nay other event, notwithstanding any investigation at any time made by or on behalf of any party hereto.

 

[Signature
Page Follows]

 

    	13

    	 

    

 

The
parties have executed this Convertible Note Purchase Agreement as of the date first written above.

 

	 	BONE BIOLOGICS, CORP.
	 	 
	 	By:	/s/
    William Jay Treat
	 	Name:	William
    Jay Treat
	 	Title:	President
    and Chief Technology Officer
	 	Address:	175
May Street

Suite 400

Edison, NJ 08837

Attn: Chief Financial Officer

	 	 	 
	 	MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
	 	 
	 	By:	/s/
    Michael J. Kawas
	 	Name:	Michael
    J. Kawas
	 	Title:	Executive
    Vice President and Chief Financial Officer
	 	Address:	125
    May Street
	Suite
    300
	Edison,
    New Jersey 08837
	Attn:
    Chief Financial Officer

 

[Signature
Page to Convertible Note Purchase Agreement]

 

    	 

    	 

    

 

SCHEDULE
1

 

(INTELLECTUAL
PROPERTY)

 

	(A) 	Copyrights

 

None

 

	(B)	Copyright Licenses

 

None

 

	(C)	Patents

 

None

 

	(D)	Patent Licenses:

 

Exclusive
License Agreement, dated March 15, 2006, between Grantor and the Regents of the University of California (“Regents”),
as amended by that certain First Amendment to License Agreement No. 2006-03-0536, dated September 1, 2007, as further amended
by that certain Second Amendment to Exclusive License Agreement, dated May 29, 2008, and as further amended by that certain Third
Amendment to Exclusive License Agreement, dated December 4, 2008, each between the Regents and Grantor.

 

	(E)	Trademarks

  

None

 

	(F)	Trademark Licenses

 

None

 

	(G)	Trade Secret Licenses

 

None

 

	(H)	Intellectual Property Exception

 

None

 

    	 

    	 

    

 

EXHIBIT
A

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE
EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.

 

BONE
BIOLOGICS, CORP.

 

CONVERTIBLE
PROMISSORY NOTE

 

	$3,659,328	September
    19, 2014

 

SECTION
1. General. For value received, BONE BIOLOGICS,
CORP., a Delaware corporation (the “Maker”), hereby promises to pay to MUSCULOSKELETAL TRANSPLANT FOUNDATION,
INC., a District of Columbia non-profit corporation, or its successors/assigns, the principal amount of Three Million Six
Hundred Fifty Nine Thousand Three Hundred and Twenty Eight Dollars ($3,659,328), payable on the Maturity Date (as hereinafter
defined) (subject to prepayment in whole or in part in the manner provided in Section 3 hereof), in such coin or currency of the
United States of America as at the time of payment shall be legal tender therein for the payment of public and private debts;
and, to pay interest on the unpaid balance of the principal amount hereof from the date hereof at a rate equal to eight and one-half
percent (8.5%) per annum, compounded annually, in like coin or currency, together with payment of the principal hereunder, and
to pay interest at such rate on any overdue principal and (to the extent permitted by law) on any overdue interest, from the due
date hereof until the obligation of the Maker with respect to the payment thereof shall be discharged; all payments and prepayments
of principal of this Note and all payments of the interest on this Note to be made at 125 May Street, Suite 300, Edison, New Jersey
08837, or such other location as shall be specified in writing by the holder of this Note to the Maker.

 

SECTION
2. Definitions. As used herein, the following terms
shall have the following respective meanings:

 

The
term “Affiliate” shall mean any person who is a director or officer of the subject referenced or is a person
or entity which directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control
with the subject referenced; and, for purposes of the foregoing, the term “control” shall mean the possession,
directly or indirectly of the power to direct or cause the direction of the management and policies of a party, whether through
the ownership of voting securities, by contract or otherwise.

 

The
term “Common Stock” shall mean shares of the common stock, $0.001 par value, of the Maker as constituted on
the Issuance Date (including any stock into which it may be changed, reclassified or converted).

 

    	A-1

    	 

    

 

The
term “Conversion Price” shall have the meaning set forth in Section 7.1 hereof.

 

The
term “Conversion Rights” shall have the meaning set forth in Section 7 hereof.

 

The
term “Convertible Securities” shall have the meaning set forth in Paragraph (b) of Section 7.5 hereof.

 

The
term “Equity Securities” shall have the meaning set forth under Rule 405 (or any successor rule) promulgated
by the United States Securities and Exchange Commission under the Securities Act, whether or not said act applies to the Maker
or its securities.

 

The
term “Event of Default” shall have the meaning set forth in Section 6 hereof.

 

The
term “Excluded Shares” shall have the meaning set forth in Paragraph (a) of Section 7.5 hereof.

 

The
term “Issuance Date” shall mean the date first set forth in this Note.

 

The
term “Maker” shall mean Bone Biologics, Corp., a Delaware corporation, the maker of this Note, and shall also
mean any successor Maker which shall become such in the manner prescribed in Section 5 hereof.

 

The
term “Maturity Date” shall mean March 31, 2015.

 

The
term “Next Equity Financing” shall mean a private placement of Equity Securities of the Company in an amount
up to $10,000,000.

 

The
term “New Note” shall have the meaning set forth in Section 7.2 hereof.

 

The
term “Note” shall mean this Note and any Note executed and delivered by the Maker in exchange or replacement
for this Note pursuant to Section 8 hereof.

 

The
term “Options” shall have the meaning set forth in Paragraph (b) of Section 7.5 hereof.

 

The
term “Purchase Agreement” shall mean the Convertible Note Purchase Agreement dated even date herewith
between the Maker and Musculoskeletal Transplant Foundation, Inc.

 

The
term “Securities Act” shall mean the Securities Act of 1933, as amended.

 

The
term “Subject Valuation” shall mean the quotient obtained by dividing (x) the subscription price per share
or other unit of the principal Equity Security sold or to be sold in the Next Equity Financing (calculated on the basis of the
same subscription price payable by investors generally) by (y) the number of shares of Common Stock with respect to which such
share or other unit is then or will become exercisable, convertible or exchangeable, as the case may be.

 

    	A-2

    	 

    

 

The
term “Subsidiary” shall mean: (x) any present or future Maker at least a majority of the outstanding voting
stock of which shall at the time be owned, directly or indirectly through Subsidiaries, by the Maker, or which is otherwise controlled
by the Maker, and (y) any partnership, association, joint venture or other entity in which the Maker, directly or indirectly,
through Subsidiaries, has a 50% or more equity interest at the time or which is otherwise controlled by the Maker. For purposes
hereof, outstanding voting stock shall be deemed to be capital stock of any class or classes, however designated, having ordinary
voting power for the election of the members of the board of directors or other governing body of such Maker.

 

SECTION
3. Optional Prepayment. The Maker shall have the right
at any time prior to the Maturity Date to prepay the whole, or any part, of the unpaid principal amount of this Note, without
premium or penalty, provided that interest on the principal amount hereof to be so prepaid accrued to the date of such prepayment
shall be paid concurrently therewith and subject to exercise (at any time prior to the date fixed for prepayment) of the Conversion
Rights contained in Section 7 hereof. Notices of prepayment shall be given by the Maker by mail and shall be mailed to the holder
of this Note not less than 30 days from the date fixed for prepayment. In case this Note is to be prepaid in part only, such notice
shall specify the principal amount hereof to be prepaid. Upon giving of notice of prepayment as aforesaid, this Note or portion
hereof so specified for prepayment shall on the prepayment date specified in such notice become due and payable, and from and
after the prepayment date so specified (unless the Maker shall default in making such prepayment) interest on the principal of
this Note or portion hereof so specified for prepayment shall cease to accrue, and the principal of this Note or portion hereof
so specified for prepayment shall be paid by the Maker at the prepayment price aforesaid.

 

SECTION
4. General Covenants. The Maker covenants and agrees
with the holder of this Note as follows:

 

4.1
The Maker shall punctually pay or cause to be paid the principal of and interest on this Note according to the terms hereof.

 

4.2
The Maker shall and shall cause each Subsidiary to:

 

(a)
pay and discharge promptly, or cause to be paid and discharged promptly all taxes, assessments and governmental charges or levies
imposed upon it or upon its income or upon any of its property, real, personal or mixed, or upon any part thereof, as well as
all claims of any kind (including claims for labor, materials and supplies which, if unpaid, might by law become a lien or charge
upon its property), provided, however, that neither the Maker nor any Subsidiary shall be required to pay any such tax, assessment,
charge, levy or claim if the amount, applicability or validity thereof shall currently be contested in good faith by appropriate
proceedings and if the Maker or such Subsidiary shall have set aside on its books reserves (segregated to the extent required
by sound accounting practice) reasonably deemed by it adequate with respect thereto;

 

(b)
except as otherwise specifically permitted in this Note and as contemplated by Section 5 hereof, do or cause to be done all things
necessary or appropriate to preserve and keep in full force and effect its corporate existence, rights and franchises, and use
its best efforts to qualify as a foreign Maker entitled to do business in every jurisdiction in which the failure so to qualify
would materially adversely effect on its business or properties;

 

    	A-3

    	 

    

 

(c)
comply in all material respects with all applicable federal, state, county and municipal laws, ordinances, rules, and regulations
now in force or hereafter enacted; and

 

(d)
maintain its books, accounts and records in accordance with generally accepted accounting principles and permit any person or
entity designated by reasonable, advance notice from the holder of this Note to visit and inspect at reasonable hours any of its
properties, books and financial records, and to make copies thereof and take extracts therefrom.

 

4.3
The Maker shall give prompt written notice to the holder of this Note after any officer of the Maker knows or has reason to know
that: (a) a default or an Event of Default hereunder, or any condition, event or act which with the giving of notice or the passage
or lapse of time, or both, would constitute such an Event of Default, has occurred and is continuing, together with a specification
of the same and the steps if any being taken to remedy the same; or (b) any other circumstance or event would have a material
adverse effect on the Maker’s business, properties, operations, income, assets, prospects or condition, financial or otherwise.

 

SECTION
5. Consolidation Merger or Disposition of Assets.
The Maker shall not consolidate with, merge into, or sell or otherwise dispose of all or substantially all its properties as an
entirety to, any person unless:

 

(a)
the successor formed by or resulting from such consolidation or merger or to which such sale or other disposition shall have been
made shall be a Maker organized under the laws of the United States of America or any State, district or territory thereof;

 

(b)
such successor Maker shall expressly assume the due and punctual payment of the principal of and interest on this Note according
to its tenor, and the due and punctual performance and observance of all the covenants, agreements and conditions of this Note
to be performed or observed by the Maker to the same extent as if such successor Maker had been the original maker of this Note
(and such assumption shall, upon the request of the holder of this Note, be evidenced by the endorsing of an appropriate legend
upon this Note, and any Note executed pursuant to Section 8 hereof after such assumption shall, unless executed in the name of
such Maker, have a similar legend endorsed thereon); and

 

(c)
immediately after such consolidation, merger, sale or other disposition, such successor Maker shall not be in default in the performance
of any of the covenants, agreements or conditions contained in this Note and no condition, act or event (with the giving of notice,
passage of time, or otherwise) would result in such default.

 

    	A-4

    	 

    

 

SECTION
6. Events of Default and Remedies.

 

6.1
The entire unpaid principal amount of this Note, together with all accrued interest hereon, at the option of the holder hereof
exercised by written notice to the Maker, shall forthwith become and be due and payable if any one or more of the following events
(herein called “Events of Default”) shall have occurred (for any reason whatsoever and whether such happening
shall be voluntary or involuntary or come about or be effected by operation of law or pursuant to or in compliance with any judgment,
decree or order of any court or any order, rule or regulation of any administrative or governmental body) and be continuing at
the time of such notice, that is to say:

 

(a)
if default shall be made in the due and punctual payment of the principal of this Note when and as the same shall become due and
payable, whether at maturity, by acceleration or otherwise, and such default shall have continued for a period of ten days;

 

(b)
if default shall be made in the due and punctual payment of any interest on this Note when and as such interest shall become due
and payable, and such default shall have continued for a period of ten days;

 

(c)
if default shall be made in the performance or observance of any covenant, agreement or condition contained in Section 5 or Section
7.6 hereof;

 

(d)
if default shall be made in the performance or observance of any of the other covenants, agreements or conditions of the Maker
or any Subsidiary contained in this Note or in the Purchase Agreement, and such default shall have continued for a period of 30
days;

 

(e)
if any representation or warranty made by the Maker under the Purchase Agreement or in any document or certificate furnished by
the Maker pursuant thereto shall prove to be inaccurate in any material respect when made;

 

(f)
if this Note or the Purchase Agreement shall cease to be enforceable in accordance with its terms against the Maker, or the Maker
shall so state in writing;

 

(g)
if the Maker or any Subsidiary shall default beyond any period of grace provided with respect thereto in the payment of principal
of, premium, if any, or interest on any obligation in respect of borrowed money when due, whether by acceleration or otherwise;
or if the Maker or any Subsidiary shall default in the performance or observance of any other agreement, term or condition contained
in such obligation or in any agreement under which any such obligation is created, if the effect of any such default is to cause
the holder or holders of such obligations (or a trustee on behalf of such holder or holders) to cause such obligation to become
due prior to the date of its stated maturity, unless such holder or holders or trustee shall have waived such default after its
occurrence or unless such holder or holders or trustee shall have failed to give any notice required to create an event of default
thereunder;

 

    	A-5

    	 

    

 

(h)
if final judgment for the payment of money shall be rendered by a court of record against the Maker or any Subsidiary and the
Maker or such Subsidiary shall not discharge the same or provide for its discharge in accordance with its terms, or shall not
procure a stay of execution thereon within 30 days from the date of entry thereof and, within the period during which execution
of such judgment shall have been stayed, appeal therefrom, and cause the execution thereof to be stayed during such appeal;

 

(i)
if the Maker or any Subsidiary shall: (i) admit in writing its inability to pay its debts generally as they become due; (ii) file
a petition in bankruptcy or a petition to take advantage of any insolvency act; (iii) make an assignment for the benefit of creditors;
(iv) consent to the appointment of a receiver of itself or of the whole or any substantial part of its property; (v) on a petition
in bankruptcy filed against it, be adjudicated a bankrupt; or (vi) file a petition or answer seeking reorganization or arrangement
under the Federal bankruptcy laws or any other applicable law or statute of the United States of America or any State, district
or territory thereof;

 

(j)
if a court of competent jurisdiction shall enter, except at the direct or indirect request of the holder of this Note, an order,
judgment, or decree appointing, without the consent of the Maker or any Subsidiary, a receiver of the Maker or any Subsidiary
or of the whole or any substantial part of its property, or approving a petition filed against it seeking reorganization or arrangement
of the Maker or any Subsidiary under the Federal bankruptcy laws or any other applicable law or statute of the United States of
America or any State, district or territory thereof, and such order, judgment or decree shall not be vacated or set aside or stayed
within 60 days from the date of entry thereof; or

 

(k)
if, under the provisions of any other law for the relief or aid of debtors, any court of competent jurisdiction shall assume custody
or control of the Maker or any Subsidiary or of the whole or any substantial part of its property and such custody or control
shall not be terminated or stayed within 60 days from the date of assumption of such custody or control.

 

6.2
In the case any one or more of the Events of Default specified in Section 6.1 hereof shall have occurred and be continuing, the
holder of this Note may proceed to protect and enforce its rights either by suit in equity and/or by action at law, whether for
the specific performance of any covenant or agreement contained in this Note, or the holder of this Note may proceed to enforce
the payment of all sums due upon this Note or to enforce any other legal or equitable right of the holder of this Note. In the
event an Event of Default shall have occurred and the holder of this Note shall employ attorneys, or incur other costs and expenses
for the collection of payments due or to become due, or for the enforcement or performance or observance of any obligation or
agreement of the Maker under this Note, the Maker agrees that it will pay to the holder, on demand, the reasonable fees of such
attorney together with all other costs and expenses incurred by the holder.

 

    	A-6

    	 

    

 

6.3
No remedy herein conferred upon the holder is intended to be exclusive of any other remedy and each and every such remedy shall
be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity
or by statute or otherwise.

 

6.4
No course of dealing between the Maker and the holder or any delay on the part of the holder hereof in exercising any rights hereunder
shall operate as a waiver of any rights of the holder hereof.

 

SECTION
7. Conversion. The holder of this Note shall have
conversion rights as follows (the “Conversion Rights”):

 

7.1
Permissive and Mandatory Conversion. The entire outstanding principal amount of this Note, and all accrued and unpaid
interest hereon, or any portion thereof, may be convertible to Common Stock in Maker at any time upon the request of Holder, in
the manner set forth in Section 7.2. Further, to the extent not previously converted to Common Stock in Maker at the request of
Holder: (i) fifty-percent (50%) of the face value of this Note, plus fifty-percent (50%) of all accrued and unpaid interest hereon,
shall be converted to Common Stock in Maker upon the Next Equity Financing; and (ii) all remaining value in this Note, plus all
remaining accrued and unpaid interest hereon, shall be converted to Common Stock in Maker, following the Next Equity Financing,
upon the consummation of Maker’s initial public offering. The number of shares of Common Stock issued upon such conversion
shall be determined by dividing the amount to be converted by the conversion price, determined as hereafter provided, in effect
on the date of such partial or complete conversion (“Conversion Price”). Upon any conversion of this Note,
or any portion hereof, appropriate cash adjustment shall be made for or on account of any interest accrued up to the date of conversion,
or for or on account of any dividends on any shares of Common Stock issued upon such conversion. The initial Conversion Price
shall be $1.00. Such initial Conversion Price shall be subject to adjustment as hereinafter provided.

 

7.2
Mechanics of Conversion. Upon the occurrence of any of the enumerated events set forth in the Section 7.1, the holder
of this Note shall surrender this Note (accompanied, if requested by the Maker, by a duly executed instrument of transfer), at
the office of the Maker, and shall state in writing the name or names in which the certificate or certificates for shares of Common
Stock are to be issued. The Maker shall, as soon as practicable thereafter, issue and deliver at such office to such holder, or
to the nominee or nominees of such holder, a certificate or certificates for the number of shares of Common Stock to which such
holder shall be entitled as aforesaid; and in the event of conversion of only a part of the amount outstanding hereon, the Maker
shall execute and deliver to or on the order of the holder hereof at said office, at the expense of the Maker, a new note (“New
Note”) in an amount equal to the unconverted portion hereof, which New Note shall be dated and bear interest from the
date to which interest shall have been paid on such converted portion. Such conversion shall be deemed to have been made immediately
prior to the close of business on (i) the date of such surrender of this Note as aforesaid, and the person or persons entitled
to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or
holders of such shares of Common Stock as of such date. If the conversion is in connection with an underwritten public offering
of securities registered pursuant to the Securities Act, the conversion may, at the option of any holder hereof, be conditioned
upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event any persons entitled
to receive Common Stock upon conversion of this Note, shall not be deemed to have converted this Note, or portion hereof, until
immediately prior to the closing of such sale of securities.

 

    	A-7

    	 

    

 

7.3
Conversion Price Adjustments for Certain Splits and Combinations. The Conversion Price shall be subject to adjustment
form time to time as follows: 

 

(a)
Stock Splits and Dividends. In the event the Maker should at any time after the Issuance Date fix a record date
for the effectuation of a split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common
Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or Options or Convertible
Securities entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock without payment of
any consideration by such holder for the additional shares of Common Stock, Options or Convertible Securities (including the additional
shares of Common Stock issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend
distribution, split or subdivision if no record date is fixed), the Conversion Price shall be appropriately decreased so that
the number of shares of Common Stock issuable on conversion hereof shall be increased in proportion to such increase of the aggregate
of shares of Common Stock outstanding and those issuable with respect to such Options or Convertible Securities with the number
of shares issuable with respect to Options or Convertible Securities determined from time to time as provided in Section 7.3(c)
below.

 

(b)
Reverse Stock Splits. If the number of shares of Common Stock outstanding at any time after the Issuance Date is
decreased by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the
Conversion Price shall be appropriately increased so that the number of shares of Common Stock issuable on conversion hereof shall
be decreased in proportion to such decrease in outstanding shares.

 

(c)
The following provisions shall apply for purposes of this Section 7.3:

 

(i)
The aggregate maximum number of shares of Common Stock deliverable upon conversion, exchange or exercise of any Options or Convertible
Securities (assuming the satisfaction of any conditions to convertibility, exchangeability or exercisability, including, without
limitation, the passage of time, but without taking into account potential anti-dilution adjustments) shall be deemed to have
been issued at the time such Options or Convertible Securities were issued.

 

    	A-8

    	 

    

 

(ii)
In the event of any change in the number of shares of Common Stock deliverable or in the consideration payable to the Maker upon
conversion or exercise of such Options or Convertible Securities including, but not limited to, a change resulting from the anti-dilution
provisions thereof, the Conversion Price, to the extent in any way affected by or computed using such Options or Convertible Securities,
shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of Common Stock or
any payment of such consideration upon the conversion, exchange or exercise of such Options or Convertible Securities.

 

(iii)
Upon the termination or expiration of the convertibility, exchangeability or exercisability of any such Options or Convertible
Securities, the Conversion Price, to the extent in any way affected by or computed using such Options or Convertible Securities,
shall be recomputed to reflect the issuance of only the number of shares of Common Stock (and Options or Convertible Securities
which remain convertible, exchangeable or exercisable) actually issued upon the conversion, exchange or exercise of such Options
or Convertible Securities.

 

7.4
Other Distributions. While this Note is outstanding, unless waived by the holder hereof the Maker shall not declare
a distribution (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this Section
7) on the Common Stock payable in securities of other persons, evidences of indebtedness issued by the Maker or other persons,
assets (excluding cash dividends) or options or rights not referred to in Section 7.3(a). 

 

7.5
Conversion Price Adjustments for Certain Issuance of Securities. Notwithstanding anything to the contrary herein,
the provisions of this Section 7.5 shall neither apply to nor be triggered by the Merger.

 

(a)
If and whenever after the Issuance Date, the Maker shall issue or sell any shares of its Common Stock for a consideration per
share less than the Conversion Price in effect immediately prior to the time of such issue or sale, or without consideration,
then, forthwith upon each such issue or sale, the Conversion Price shall be reduced to the price equal to the consideration per
share in such issuance or sale. In addition, the provisions of this paragraph (a) shall not apply to the issuance of any Excluded
Shares. For purposes hereof, “Excluded Shares” shall refer to any issuances of shares of Common Stock (or options
therefor) from time to time to employees, consultants, service providers, vendors and directors of the Maker directly or pursuant
to stock option plans authorized by the Board of Directors of the Maker.

 

    	A-9

    	 

    

 

(b)
For purposes of this Section 7.5 the following additional clauses shall apply:

 

(i)
Issuance of Rights or Options. In case at any time the Maker shall in any manner grant (whether directly or by assumption
in a merger or otherwise) any rights to subscribe for or to purchase, or any options for the purchase of, Common Stock or any
stock or securities convertible into or exchangeable for Common Stock (such rights or options being herein called “Options”
and such convertible or exchangeable stock or securities being herein called “Convertible Securities”) whether
or not such Options or the right to convert or exchange any such Convertible Securities are immediately exercisable, and the price
per share for which Common Stock is issuable upon the exercise of such Options or upon the conversion or exchange of such Convertible
Securities (determined by dividing (x) the total amount, if any, received or receivable by the Maker as consideration for the
granting of such Options, plus the aggregate amount of additional consideration payable to the Maker upon the exercise of all
such Options, plus, in the case of such Options which relate to Convertible Securities, the aggregate amount of additional consideration,
if any, payable upon the issue or sale of such Convertible Securities and upon the conversion or exchange thereof, by (y) the
total maximum number of shares of Common Stock issuable upon the exercise of such Options or upon the conversion or exchange of
all such Convertible Securities issuable upon the exercise of such Options) shall be less than the Conversion Price in effect
immediately prior to the time of the granting of such Options, then the total maximum number of shares of Common Stock issuable
upon the exercise of such Options or upon conversion or exchange of the total maximum amount of such Convertible Securities issuable
upon the exercise of such Options shall be deemed to have been issued for such price per share as of the date of granting of such
Options and thereafter shall be deemed to be outstanding. Except as otherwise provided in sub-paragraph (iii) of this paragraph
(b), no adjustment of the Conversion Price shall be made upon the actual issue of such Common Stock or of such Convertible Securities
upon exercise of such Options or upon the actual issue of such Common Stock upon conversion or exchange of such Convertible Securities.

 

(ii)
Issuance of Convertible Securities. In case the Maker shall in any manner issue (whether directly or by assumption
in a merger or otherwise) or sell any Convertible Securities, whether or not the rights to exchange or convert any such Convertible
Securities are immediately exercisable, and the price per share for which Common Stock is issuable upon such conversion or exchange
(determined by dividing (x) the total amount received or receivable by the Maker as consideration for the issue or sale of such
Convertible Securities, plus the aggregate amount of additional consideration, if any, payable to the Maker upon the conversion
or exchange thereof, by (y) the total maximum number of shares of Common Stock issuable upon the conversion or exchange of all
such Convertible Securities) shall be less than the Conversion Price in effect immediately prior to the time of such issue or
sale, then the total maximum number of shares of Common Stock issuable upon conversion or exchange of all such Convertible Securities
shall be deemed to have been issued for such price per share as of the date of the issue or sale of such Convertible Securities
and thereafter shall be deemed to be outstanding, provided that (I) except as otherwise provided in sub-paragraph (iii) of paragraph
(b), no adjustment of the Conversion Price shall be made upon the actual issue of such Common Stock upon conversion or exchange
of such Convertible Securities, and (II) if any such issue or sale of such Convertible Securities is made upon exercises of any
Options to purchase any such Convertible Securities for which adjustments of the Conversion Price have been or are to be made
pursuant to other provisions of this sub-paragraph (ii), no further adjustment of the Conversion Price shall be made by reason
of such issue or sale.

 

    	A-10

    	 

    

 

(iii)
Change in Option Price or Exercise Rate. Upon the happening of any of the following events, namely, if the purchase
price provided for in any Option referred to in sub-paragraph (i) of this paragraph (b), the additional consideration, if any,
payable upon the conversion or exchange of any Convertible Securities referred to in sub-paragraphs (i) or (ii) of this paragraph
(b), or the rate at which any Convertible Securities referred to in paragraph (a) of this Section 7.5 are convertible into or
exchangeable for Common Stock shall change at any time (other than under or by reason of provisions designed to protect against
dilution), the Conversion Price in effect at the time of such event shall forthwith be readjusted to the Conversion Price which
would have been in effect at such time had such Options or Convertible Securities still outstanding provided for such changed
purchase price, additional consideration or conversion rate, as the case may be, at the time initially granted, issued or sold;
and on the expiration of any such Option or the termination of any such right to convert or exchange such Convertible Securities,
the Conversion Price then in effect hereunder shall forthwith be increased to the Conversion Price which would have been in effect
at the time of such expiration or termination had such Option or Convertible Securities, to the extent outstanding immediately
prior to such expiration or termination, never been issued, and the Common Stock issuable thereunder shall no longer be deemed
to be outstanding. If the purchase price provided for in any such Option referred to in sub-paragraph (i) of this paragraph (b)
or the rate at which any Convertible Securities referred to in sub-paragraph (i) or (ii) of this paragraph (b) are convertible
into or exchangeable for Common Stock shall be reduced at any time under or by reason of provisions with respect thereto designed
to protect against dilution, then, in case of the delivery of Common Stock upon the exercise of any such Option or upon conversion
or exchange of any such Convertible Securities, the Conversion Price then in effect hereunder shall forthwith be adjusted to such
respective amount as would have been obtained had such Option or Convertible Securities never been issued as to such Common Stock
and had adjustments been made upon the issuance of the shares of Common Stock delivered as aforesaid, but only if as a result
of such adjustment the Conversion Price then in effect hereunder is thereby reduced.

 

    	A-11

    	 

    

 

7.6
Recapitalizations. If at any time or from time to time there shall be a recapitalization or reclassification of
the Common Stock (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this
Section 7) provision shall be made so that the holder of this Note shall thereafter be entitled to receive upon conversion hereof,
the number of shares of stock or other securities or property of the Maker or otherwise, to which a holder of Common Stock deliverable
upon conversion would have been entitled on such recapitalization or reclassification. In any such case, appropriate adjustment
shall be made in the application of the provisions of this Section 7 with respect to the rights of the holder of this Note after
the recapitalization or reclassification to the end that the provisions of this Section 7 (including adjustment of the Conversion
Price then in effect and the number of shares purchasable upon conversion hereof) shall be applicable after that event and be
as nearly equivalent as practicable.

 

7.7
No Impairment. The Maker will not, through any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Maker, but will at all times in good faith assist in the carrying
out of all the provisions of this Section 7 and in the taking of all such action as may be necessary or appropriate in order to
protect the Conversion Rights of the holder of this Note against impairment.

 

7.8
No Fractional Shares and Certificate as to Adjustments.

 

(a)
No fractional shares shall be issued upon the conversion of this Note. In lieu of fractional shares, the Maker will pay cash in
an amount equal to the fair value of such fractional shares, based on the fair market value of the shares of Common Stock, as
determined in good faith by the Board of Directors, as of the time when those who would otherwise be entitled to receive such
fractional shares is determined. The number of shares issuable upon such conversion shall be determined on the basis of the total
amount hereof, the holder is at the time converting into Common Stock and the number of shares of Common Stock issuable upon such
aggregate conversion.

 

(b)
Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Section 7, the Maker, at its expense,
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to each holder
of this Note a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment
or readjustment is based. In the event of a Next Equity Financing a notice of adjustment as aforesaid of the Conversion Price
then to be effective shall be delivered no later than 30 days prior to such event. The Maker shall, upon the written request at
any time of any holder of this Note furnish or cause to be furnished to such holder a like certificate setting forth (i) such
adjustment and readjustment, (ii) the Conversion Price at the time in effect, and (iii) the number of shares of Common Stock and
the amount, if any, of other property which at the time would be received upon the conversion hereof.

 

    	A-12

    	 

    

 

7.9
Notices of Record Date. In the event of any taking by the Maker of a record of the holders of any class of securities
for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other
distribution, any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities
or property, or to receive any other right, the Maker shall mail to the holder of this Note at least 10 days prior to the date
specified therein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution
or right, and the amount and character of such dividend, distribution or right.

 

7.10
Reservation of Stock Issuable Upon Conversion. The Maker shall at all times reserve and keep available out of its
authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of this Note, such number of
its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all amounts outstanding on this
Note; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion
of all amounts outstanding on this Note, in addition to such other remedies as shall be available to the holder of this Note,
the Maker will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued
shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging
in best efforts to obtain the requisite shareholder approval of any necessary amendment to the Maker’s certificate of incorporation.

 

7.11
Notices. Any notice required by the provisions of this Section 7 to be given to the holder of this Note shall be
deemed given if deposited in the United States mail, postage prepaid, and addressed to such holder at his address appearing on
the books of the Maker. In case at any time:

 

(a)
the Maker shall declare to the holders of its shares of Common Stock any cash dividend at a rate in excess of the rate of the
last cash dividend theretofore paid;

 

(b)
the Maker shall declare any dividend upon its shares of Common Stock payable in stock or make any special dividend or other distribution
(other than a cash dividend to the holders of its shares of Common Stock);

 

(c)
the Maker shall offer for subscription pro rata to the holders of its shares of Common Stock any additional shares of stock of
any class or other rights;

 

    	A-13

    	 

    

 

(d)
there shall be a recapitalization or reclassification of the Common Stock; or

 

(e)
there shall be a Next Equity Financing;

 

then,
in any one or more of said cases, the Maker shall give written notice to each holder of this Note of the date on which (A) the
books of the Maker shall close or a record shall be taken for such dividend, distribution or subscription rights, or (B) such
reclassification or recapitalization; or Next Equity Financing, shall take place, as the case may be. Such notice shall also specify
the date as of which the holders of shares of Common Stock of record shall participate in such dividend, distribution or subscription
rights or shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such recapitalization
or reclassification, as the case may be. Such written notice shall be given at least 30 days prior to the action in question and
not less than 30 days prior to the record date or the date on which the Maker’s transfer books are closed in respect thereto.

 

7.12
Taxes. The issuance of certificates of shares of Common Stock upon the conversion of this Note shall be made without
charge to the holder thereof for any issuance tax in respect thereto; provided, however, that the Maker shall not be required
to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name
other than that of the holder of this Note.

 

7.13
Closing of Books. The Maker will at no time close its transfer books against the transfer of any shares of Common
Stock issued or issuable upon the conversion of this Note in any manner which interferes with the timely conversion of this Note.

 

SECTION
8. Exchange or Replacement of Note.

 

8.1
The holder of this Note, at its option, may in person or by duly authorized attorney surrender this Note for exchange, at the
principal executive offices of the Maker, and at the expense of the Maker receive in exchange therefor a new Note in the same
aggregate principal amount as the aggregate unpaid principal amount of the Note so surrendered, bearing interest at the same annual
rate as the Note so surrendered and otherwise in substantially the form of the Note so surrendered, each such new Note to be dated
as of the date to which interest has been paid on the note so surrendered and to be in such principal amount and payable to the
holder of this Note. Five days’ prior written notice of the holders intention to make such exchange shall be given to the
Maker.

 

8.2
Upon receipt by the Maker of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note, and (in case
of loss, theft or destruction) of indemnity reasonably satisfactory to it, and upon surrender and cancellation of this Note, if
mutilated, the Maker, upon reimbursement to it of all reasonable expenses incidental thereto, will make and deliver a new Note,
of like tenor, in lieu of this Note. Any Note made and delivered in accordance with the provisions of this Section 8 shall be
dated as of the date to which interest has been paid on this Note.

 

    	A-14

    	 

    

 

SECTION
9. Notices. All notices, requests or instructions
hereunder shall be in writing and delivered personally or sent by registered or certified mail, postage prepaid as follows:

 

	 	(1)	if to the Maker:
	 	 	 
	 	 	Bone Biologics, Corp.
	 	 	175 May Street, Suite 400
	 	 	Edison, NJ 08837
	 	 	Attn: Chief Financial Officer
	 	 	 
	 	(2)	if to the holder of this Note:
	 	 	 
	 	 	Musculoskeletal Transplant Foundation, Inc.
	 	 	125 May Street, Suite 300
	 	 	Edison, New Jersey 08837
	 	 	Attn: Chief Financial Officer

 

Any
of the above addresses may be changed at any time by notice given as provided above; provided, however, that any such notice of
change of address shall be effective only upon receipt.

 

SECTION
10. Captions. Captions and section titles contained
herein are inserted as a matter of convenience and for reference only and are not intended to define, limit, extend or describe
the scope of this Note or the intent of any provision hereof.

 

SECTION
11. Severability. In the event that one or more of
the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other provisions of this Note, but this Note shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein.

 

SECTION
12. Governing Law. This Note shall be governed by
and construed in accordance with the laws of the State of Delaware applicable to agreements made and to be performed entirely
within such state.

 

SECTION
13. Related Agreements. This Note is issued pursuant
to the Purchase Agreement and is entitled to the benefits thereof. Copies of such agreement may be obtained by any holder of this
Note at the principal executive offices of the Maker.

 

[Signature
Page Follows]

 

    	A-15

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Note as of the date first above written.

 

	ATTEST:	 	BONE BIOLOGICS, CORP.
	 	 	 	 	 
	By:	 	 	By:	 
	Name:	 	 	Name:	William
    Jay Treat
	Title:	 	 	Title:	President
    and Chief Technology Officer

 

[Signature
Page to Convertible Promissory Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]